Zevra Therapeutics (ZVRA) Change in Receivables (2019 - 2026)
Zevra Therapeutics (ZVRA) posted Change in Receivables of -$6.9 million for Q1 2026, down 208.21% on a QoQ basis from $6.4 million in Q4 2025, and down 426.85% year-over-year from $2.1 million in Q1 2025.
Zevra Therapeutics (ZVRA) Change in Receivables (2019 - 2026) Analysis & Trends
Zevra Therapeutics' Change in Receivables history runs 8 years deep, the most recent figure standing at -$6.9 million for Q1 2026.
- Quarterly Change in Receivables fell 426.85% year-over-year to -$6.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.0 million (down 30.91% YoY) and the FY2025 annual result came in at $12.0 million, up 274.39% from the prior year.
- Change in Receivables was -$6.9 million for Q1 2026 at Zevra Therapeutics, down from $6.4 million in the prior quarter.
- Across five years, Change in Receivables topped out at $7.4 million in Q4 2023 and bottomed at -$9.1 million in Q1 2024.
- A 5-year average of $827588.2 and a median of $1.8 million in 2022 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2022 — Change in Receivables surged 2436.26% — and 2024, when it plunged 1801.89%.
- Zevra Therapeutics' Change in Receivables stood at $2.1 million in 2022, then surged by 250.42% to $7.4 million in 2023, then plunged by 63.5% to $2.7 million in 2024, then jumped by 134.17% to $6.4 million in 2025, then sank by 208.21% to -$6.9 million in 2026.
- Business Quant data shows ZVRA's Change in Receivables at -$6.9 million in Q1 2026, $6.4 million in Q4 2025, and -$1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 75.30 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.84 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Zevra Therapeutics | 239.71 Mn | 39.10 Mn | 34.32 Mn | -6.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.89 Mn |
| Mar 31, 2026 | -6.89 Mn |
| Dec 31, 2025 | 6.37 Mn |
| Dec 31, 2025 | 6.37 Mn |
| Sep 30, 2025 | -1.36 Mn |
| Sep 30, 2025 | -1.36 Mn |
| Jun 30, 2025 | 4.86 Mn |
| Jun 30, 2025 | 4.86 Mn |
| Mar 31, 2025 | 2.11 Mn |
| Mar 31, 2025 | 2.11 Mn |
| Dec 31, 2024 | 2.72 Mn |
| Dec 31, 2024 | 2.72 Mn |
| Sep 30, 2024 | -1.16 Mn |
| Sep 30, 2024 | -1.16 Mn |
| Jun 30, 2024 | 642,000.00 |
| Jun 30, 2024 | 642,000.00 |
| Mar 31, 2024 | -9.07 Mn |
| Mar 31, 2024 | -9.07 Mn |
| Dec 31, 2023 | 7.45 Mn |
| Dec 31, 2023 | 7.45 Mn |